The tyrphostin AG1478 inhibits proliferation and induces death of liver tumor cells through EGF receptor-dependent and independent mechanisms

Biochemical Pharmacology

Volumn 82, Issue 11, 2011, Pages 1583-1592

  Caja, Laia ^a   Sancho, Patricia ^a   Bertran, Esther ^a   Ortiz, Conrad ^a,d   Campbell, Jean S ^b   Fausto, Nelson ^b   Fabregat, Isabel ^a,c  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF BARCELONA   (Spain)

^d UNIVERSIDAD PERUANA DE CIENCIAS APLICADAS   (Peru)

Author keywords

Apoptosis; Doxorubicin; HCC; Hepatocytes; Liver; TGF beta

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; BIM PROTEIN; CASPASE 3; DOXORUBICIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; SHORT HAIRPIN RNA; TRANSFER RNA; TRANSFORMING GROWTH FACTOR BETA; X LINKED INHIBITOR OF APOPTOSIS;

ARTICLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL DEATH; CELL PROLIFERATION; CYTOTOXICITY; DNA FRAGMENTATION; DOWN REGULATION; ENZYME ACTIVATION; LIVER CELL; LIVER CELL CARCINOMA; LIVER TUMOR; PRIORITY JOURNAL; TUMOR CELL; TUMOR GROWTH; UPREGULATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; DOXORUBICIN; DRUG SYNERGISM; FETUS; GENE KNOCKDOWN TECHNIQUES; HEPATOCYTES; HUMANS; LIVER NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TYRPHOSTINS;

EID: 80255136259     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2011.08.011     Document Type: Article

References (65)

1. R.N. Aravalli, C.J. Steer, and E.N. Cressman Molecular mechanisms of hepatocellular carcinoma Hepatology 48 2008 2047 2063
2. I. Fabregat Dysregulation of apoptosis in hepatocellular carcinoma cells World J Gastroenterol 15 2009 513 520
3. J.L. Mott, and G.J. Gores Piercing the armor of hepatobiliary cancer: Bcl-2 homology domain 3 (BH3) mimetics and cell death Hepatology 46 2007 906 911 (Pubitemid 47436136)
4. C. Berasain, J. Castillo, J. Prieto, and M.A. Avila New molecular targets for hepatocellular carcinoma: the ErbB1 signaling system Liver Int 27 2007 174 185 (Pubitemid 46680720)
5. I. Fabregat, C. Roncero, and M. Fernandez Survival and apoptosis: a dysregulated balance in liver cancer Liver Int 27 2007 155 162 (Pubitemid 46680718)
6. Y. Inui, S. Higashiyama, S. Kawata, S. Tamura, J. Miyagawa, and N. Taniguchi Expression of heparin-binding epidermal growth factor in human hepatocellular carcinoma Gastroenterology 107 1994 1799 1804 (Pubitemid 24357636)
7. Y.H. Chung, J.A. Kim, B.C. Song, G.C. Lee, M.S. Koh, and Y.S. Lee Expression of transforming growth factor-alpha mRNA in livers of patients with chronic viral hepatitis and hepatocellular carcinoma Cancer 89 2000 977 982
8. C. Berasain, E.R. Garcia-Trevijano, J. Castillo, E. Erroba, M. Santamaria, and D.C. Lee Novel role for amphiregulin in protection from liver injury J Biol Chem 280 2005 19012 19020 (Pubitemid 41379606)
9. C. Berasain, M.J. Perugorria, M.U. Latasa, J. Castillo, S. Goni, and M. Santamaria The epidermal growth factor receptor: a link between inflammation and liver cancer Exp Biol Med 234 2009 713 725
10. X. Ding, L.Y. Yang, G.W. Huang, W. Wang, and W.Q. Lu ADAM17 mRNA expression and pathological features of hepatocellular carcinoma World J Gastroenterol 10 2004 2735 2739 (Pubitemid 39214513)
11. N. Fausto, J.S. Campbell, and K.J. Riehle Liver regeneration Hepatology 43 2006 S45 S53
12. I. Fabregat, A. Sanchez, A.M. Alvarez, T. Nakamura, and M. Benito Epidermal growth factor, but not hepatocyte growth factor, suppresses the apoptosis induced by transforming growth factor-beta in fetal hepatocytes in primary culture FEBS Lett 384 1996 14 18 (Pubitemid 26111923)
13. I. Fabregat, B. Herrera, M. Fernandez, A.M. Alvarez, A. Sanchez, and C. Roncero Epidermal growth factor impairs the cytochrome C/caspase-3 apoptotic pathway induced by transforming growth factor beta in rat fetal hepatocytes via a phosphoinositide 3-kinase-dependent pathway Hepatology 32 2000 528 535
14. L. Caja, C. Ortiz, E. Bertran, M.M. Murillo, M.J. Miro-Obradors, and E. Palacios Differential intracellular signalling induced by TGF-beta in rat adult hepatocytes and hepatoma cells: implications in liver carcinogenesis Cell Signal 19 2007 683 694 (Pubitemid 46275361)
15. C. Ortiz, L. Caja, P. Sancho, E. Bertran, and I. Fabregat Inhibition of the EGF receptor blocks autocrine growth and increases the cytotoxic effects of doxorubicin in rat hepatoma cells: role of reactive oxygen species production and glutathione depletion Biochem Pharmacol 75 2008 1935 1945
16. C.A. Lazaro, E.J. Croager, C. Mitchell, J.S. Campbell, C. Yu, and J. Foraker Establishment, characterization, and long-term maintenance of cultures of human fetal hepatocytes Hepatology 38 2003 1095 1106 (Pubitemid 37314818)
17. W. Tang, C.A. Lazaro, J.S. Campbell, W.T. Parks, M.G. Katze, and N. Fausto Responses of nontransformed human hepatocytes to conditional expression of full-length hepatitis C virus open reading frame Am J Pathol 171 2007 1831 1846
18. A. Sanchez, A.M. Alvarez, M. Benito, and I. Fabregat Apoptosis induced by transforming growth factor-beta in fetal hepatocyte primary cultures: involvement of reactive oxygen intermediates J Biol Chem 271 1996 7416 7422
19. C. de Juan, M. Benito, A. Alvarez, and I. Fabregat Differential proliferative response of cultured fetal and regenerating hepatocytes to growth factors and hormones Exp Cell Res 202 1992 495 500
20. M.M. Murillo, G. del Castillo, A. Sanchez, M. Fernandez, and I. Fabregat Involvement of EGF receptor and c-Src in the survival signals induced by TGF-beta1 in hepatocytes Oncogene 24 2005 4580 4587 (Pubitemid 41032621)
21. F. Valdés, A.M. Alvarez, A. Locascio, S. Vega, B. Herrera, and M. Fernandez The epithelial mesenchymal transition confers resistance to the apoptotic effects of transforming growth factor beta in fetal rat hepatocytes Mol Cancer Res 1 2002 68 78 (Pubitemid 36330212)
22. K.J. Livak, and T.D. Schmittgen Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method Methods 25 2001 402 408 (Pubitemid 34164012)
23. L. Coll-Mulet, D. Iglesias-Serret, A.F. Santidrian, A.M. Cosialls, M. de Frias, and E. Castano MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells Blood 107 2006 4109 4114 (Pubitemid 43726820)
24. I. Carmona-Cuenca, C. Roncero, P. Sancho, L. Caja, N. Fausto, and M. Fernandez Upregulation of the NADPH oxidase NOX4 by TGF-beta in hepatocytes is required for its pro-apoptotic activity J Hepatol 49 2008 965 976
25. P. Sancho, and I. Fabregat NADPH oxidase NOX1 controls autocrine growth of liver tumor cells through up-regulation of the epidermal growth factor receptor pathway J Biol Chem 285 2010 24815 24824
26. L. Caja, P. Sancho, E. Bertran, and I. Fabregat Dissecting the effect of targeting the epidermal growth factor receptor on TGF-beta-induced-apoptosis in human hepatocellular carcinoma cells J Hepatol 55 2011 351 358
27. E.C. LaCasse, D.J. Mahoney, H.H. Cheung, S. Plenchette, S. Baird, and R.G. Korneluk IAP-targeted therapies for cancer Oncogene 27 2008 6252 6275
28. J.E. Chipuk, T. Moldoveanu, F. Llambi, M.J. Parsons, and D.R. Green The BCL-2 family reunion Mol Cell 37 2010 299 310
29. L. Caja, E. Bertran, J. Campbell, N. Fausto, and I. Fabregat The transforming growth factor-beta (TGF-beta) mediates acquisition of a mesenchymal stem cell-like phenotype in human liver cells J Cell Physiol 226 2011 1214 1223
30. S. Whittaker, R. Marais, and A.X. Zhu The role of signaling pathways in the development and treatment of hepatocellular carcinoma Oncogene 29 2010 4989 5005
31. M.A. Worns, and P.R. Galle Future perspectives in hepatocellular carcinoma Dig Liver Dis 42 Suppl. 3 2010 S302 S309
32. H. Huynh Molecularly targeted therapy in hepatocellular carcinoma Biochem Pharmacol 80 2010 550 560
33. A. Altimari, M. Fiorentino, E. Gabusi, E. Gruppioni, B. Corti, and A. D'Errico Investigation of ErbB1 and ErbB2 expression for therapeutic targeting in primary liver tumours Dig Liver Dis 35 2003 332 338 (Pubitemid 41110860)
34. Z.B. Gong, J.M. Liu, and Y.M. Li Inhibitory effect of EGFR antisense oligodeoxynucleotide on human hepatoma cell line Hepatobiliary Pancreat Dis Int 4 2005 433 436
35. M. Hopfner, A.P. Sutter, A. Huether, D. Schuppan, M. Zeitz, and H. Scherubl Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma J Hepatol 41 2004 1008 1016 (Pubitemid 39575669)
36. J. Okano, K. Matsumoto, T. Nagahara, and Y. Murawaki Gefitinib and the modulation of the signaling pathways downstream of epidermal growth factor receptor in human liver cancer cells J Gastroenterol 41 2006 166 176
37. A. Huether, M. Hopfner, A.P. Sutter, D. Schuppan, and H. Scherubl Erlotinib induces cell cycle arrest and apoptosis in hepatocellular cancer cells and enhances chemosensitivity towards cytostatics J Hepatol 43 2005 661 669 (Pubitemid 41253234)
38. A. Huether, M. Hopfner, V. Baradari, D. Schuppan, and H. Scherubl EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer Biochem Pharmacol 70 2005 1568 1578 (Pubitemid 41540350)
39. T.J. Lynch, D.W. Bell, R. Sordella, S. Gurubhagavatula, R.A. Okimoto, and B.W. Brannigan Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2004 2129 2139 (Pubitemid 38637993)
40. M.J. Moore, D. Goldstein, J. Hamm, A. Figer, J.R. Hecht, and S. Gallinger Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 25 2007 1960 1966 (Pubitemid 46972777)
41. P.A. Philip, M.R. Mahoney, C. Allmer, J. Thomas, H.C. Pitot, and G. Kim Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer J Clin Oncol 23 2005 6657 6663 (Pubitemid 46190260)
42. P.J. O'Dwyer, B.J. Giantonio, D.E. Levy, J.S. Kauh, D.B. Fitzgerald, and A.B. Benson Gefitinib in advanced unresectable hepatocellular carcinoma: Results from the Eastern Cooperative Oncology Group's Study E1203 2006 ASCO annual meeting proceedings J Clin Oncol 2006 24 [Abstract 4143]
43. A.X. Zhu, K. Stuart, L.S. Blaszkowsky, A. Muzikansky, D.P. Reitberg, and J.W. Clark Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma Cancer 110 2007 581 589 (Pubitemid 47106147)
44. A.G. Ellis, M.M. Doherty, F. Walker, J. Weinstock, M. Nerrie, and A. Vitali Preclinical analysis of the analinoquinazoline AG1478, a specific small molecule inhibitor of EGF receptor tyrosine kinase Biochem Pharmacol 71 2006 1422 1434
45. Y.H. Ling, R. Lin, and R. Perez-Soler Erlotinib induces mitochondrial-mediated apoptosis in human H3255 non-small-cell lung cancer cells with epidermal growth factor receptorL858R mutation through mitochondrial oxidative phosphorylation-dependent activation of BAX and BAK Mol Pharmacol 74 2008 793 806
46. S. Takaoka, M. Iwase, M. Uchida, S. Yoshiba, G. Kondo, and H. Watanabe Effect of combining epidermal growth factor receptor inhibitors and cisplatin on proliferation and apoptosis of oral squamous cell carcinoma cells Int J Oncol 30 2007 1469 1476
47. D.B. Costa, B. Halmos, A. Kumar, S.T. Schumer, M.S. Huberman, and T.J. Boggon BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations PLoS Med 4 2007 1669 1679
48. M.S. Cragg, J. Kuroda, H. Puthalakath, D.C. Huang, and A. Strasser Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics PLoS Med 4 2007 1681 1689
49. T. Takehara, X. Liu, J. Fujimoto, S.L. Friedman, and H. Takahashi Expression and role of Bcl-xL in human hepatocellular carcinomas Hepatology 34 2001 55 61 (Pubitemid 32591483)
50. X. Lu, M. Lee, T. Tran, and T. Block High level expression of apoptosis inhibitor in hepatoma cell line expressing Hepatitis B virus Int J Med Sci 2 2005 30 35 (Pubitemid 40935434)
51. M. Notarbartolo, M. Cervello, L. Giannitrapani, M. Meli, P. Poma, and L. Dusonchet Expression of IAPs and alternative splice variants in hepatocellular carcinoma tissues and cells Ann N Y Acad Sci 1028 2004 289 293 (Pubitemid 40361830)
52. C. Augello, L. Caruso, M. Maggioni, M. Donadon, M. Montorsi, and R. Santambrogio Inhibitors of apoptosis proteins (IAPs) expression and their prognostic significance in hepatocellular carcinoma BMC Cancer 9 2009 125
53. X. Zhang, A.C. Frank, C.M. Gille, M. Daucher, J. Kabat, and S. Becker Altered regulation of extrinsic apoptosis pathway in HCV-infected HCC cells enhances susceptibility to mapatumumab-induced apoptosis Hepatol Res 39 2009 1178 1189
54. E. Carrasco-Garcia, M. Saceda, S. Grasso, L. Rocamora-Reverte, M. Conde, and A. Gomez-Martinez Small tyrosine kinase inhibitors interrupt EGFR signaling by interacting with erbB3 and erbB4 in glioblastoma cell lines Exp Cell Res 317 2011 1476 1489
55. H. Pan, J. Yu, L. Zhang, A. Carpenter, H. Zhu, and L. Li A novel small molecule regulator of guanine nucleotide exchange activity of the ADP-ribosylation factor and golgi membrane trafficking J Biol Chem 283 2008 31087 31096
56. Z.Z. Dong, D.F. Yao, M. Yao, L.W. Qiu, L. Zong, and W. Wu Clinical impact of plasma TGF-beta1 and circulating TGF-beta1 mRNA in diagnosis of hepatocellular carcinoma Hepatobiliary Pancreat Dis Int 7 2008 288 295 (Pubitemid 351895389)
57. B.C. Song, Y.H. Chung, J.A. Kim, W.B. Choi, D.D. Suh, and S.I. Pyo Transforming growth factor-beta1 as a useful serologic marker of small hepatocellular carcinoma Cancer 94 2002 175 180 (Pubitemid 34049056)
58. F. Valdés, M.M. Murillo, A.M. Valverde, B. Herrera, A. Sanchez, and M. Benito Transforming growth factor-beta activates both pro-apoptotic and survival signals in fetal rat hepatocytes Exp Cell Res 292 2004 209 218 (Pubitemid 38058277)
59. S. Vega, A.V. Morales, O.H. Ocana, F. Valdes, I. Fabregat, and M.A. Nieto Snail blocks the cell cycle and confers resistance to cell death Genes Dev 18 2004 1131 1143 (Pubitemid 38669034)
60. E. Bertran, L. Caja, E. Navarro, P. Sancho, J. Mainez, and M.M. Murillo Role of CXCR4/SDF-1alpha in the migratory phenotype of hepatoma cells that have undergone epithelial-mesenchymal transition in response to the transforming growth factor-beta Cell Signal 21 2009 1595 1606
61. S. Dooley, J. Hamzavi, L. Ciuclan, P. Godoy, I. Ilkavets, and S. Ehnert Hepatocyte-specific Smad7 expression attenuates TGF-[beta]-mediated fibrogenesis and protects against liver damage Gastroenterology 135 2008 642 659 e46
62. F. Vinals, and J. Pouyssegur Transforming growth factor beta1 (TGF-beta1) promotes endothelial cell survival during in vitro angiogenesis via an autocrine mechanism implicating TGF-alpha signaling Mol Cell Biol 21 2001 7218 7230 (Pubitemid 32953476)
63. S.E. Wang, B. Xiang, M. Guix, M.G. Olivares, J. Parker, and C.H. Chung Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab Mol Cell Biol 28 2008 5605 5620
64. Z. Shi, S. Parmar, X.X. Peng, T. Shen, R.W. Robey, and S.E. Bates The epidermal growth factor tyrosine kinase inhibitor AG1478 and erlotinib reverse ABCG2-mediated drug resistance Oncol Rep 21 2009 483 489
65. Z. Shi, A.K. Tiwari, S. Shukla, R.W. Robey, I.W. Kim, and S. Parmar Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478 Biochem Pharmacol 77 2009 781 793